HK1201745A1 - Orally disintegrating tablet compositions of lamotrigine - Google Patents

Orally disintegrating tablet compositions of lamotrigine

Info

Publication number
HK1201745A1
HK1201745A1 HK15102347.9A HK15102347A HK1201745A1 HK 1201745 A1 HK1201745 A1 HK 1201745A1 HK 15102347 A HK15102347 A HK 15102347A HK 1201745 A1 HK1201745 A1 HK 1201745A1
Authority
HK
Hong Kong
Prior art keywords
lamotrigine
orally disintegrating
disintegrating tablet
tablet compositions
compositions
Prior art date
Application number
HK15102347.9A
Other languages
English (en)
Chinese (zh)
Inventor
戈皮‧
‧文卡特什
納哈爾‧
‧弗亞斯
邁克爾‧戈斯林
賴金旺
Original Assignee
Adare Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40226529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1201745(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adare Pharmaceuticals Inc filed Critical Adare Pharmaceuticals Inc
Publication of HK1201745A1 publication Critical patent/HK1201745A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
HK15102347.9A 2007-07-02 2015-03-09 Orally disintegrating tablet compositions of lamotrigine HK1201745A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92953607P 2007-07-02 2007-07-02

Publications (1)

Publication Number Publication Date
HK1201745A1 true HK1201745A1 (en) 2015-09-11

Family

ID=40226529

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11100987.2A HK1147026A1 (en) 2007-07-02 2011-01-31 Orally disintegrating tablet compositions of lamotrigine
HK15102347.9A HK1201745A1 (en) 2007-07-02 2015-03-09 Orally disintegrating tablet compositions of lamotrigine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK11100987.2A HK1147026A1 (en) 2007-07-02 2011-01-31 Orally disintegrating tablet compositions of lamotrigine

Country Status (15)

Country Link
US (5) US7919115B2 (xx)
EP (1) EP2173172A4 (xx)
JP (2) JP5346021B2 (xx)
CN (2) CN104161733A (xx)
AR (1) AR068185A1 (xx)
AU (1) AU2008272871B2 (xx)
BR (1) BRPI0814408A2 (xx)
CA (1) CA2693072C (xx)
CL (1) CL2008001966A1 (xx)
HK (2) HK1147026A1 (xx)
NZ (1) NZ582458A (xx)
SA (1) SA08290401B1 (xx)
TW (1) TWI547282B (xx)
UY (1) UY31205A1 (xx)
WO (1) WO2009006516A1 (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
TWI547282B (zh) 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20090110716A1 (en) * 2007-10-31 2009-04-30 Frank Bunick Orally disintegrative dosage form
US20090196924A1 (en) * 2008-02-04 2009-08-06 Pramod Kharwade Controlled-release lamotrigine formulations
TWI406679B (zh) * 2009-06-06 2013-09-01 Bio Trend Pharmaceutical Co Ltd 含高劑量活性物質之口崩錠
US20110097401A1 (en) * 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8784781B2 (en) * 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
JP5309262B2 (ja) * 2009-12-02 2013-10-09 アプタリス ファーマ リミテッド フェキソフェナジン・マイクロカプセル及びそれを含む組成物
CA2819663C (en) * 2010-12-02 2019-12-24 Aptalis Pharmatech, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
SG11201507843TA (en) * 2013-03-22 2015-10-29 Adare Pharmaceuticals S R L Piperaquine microcapsules and compositions containing them
JP2015063521A (ja) * 2013-09-02 2015-04-09 科研製薬株式会社 高い薬物含有率を有する錠剤及びその製造方法
ES2750323T3 (es) 2014-01-10 2020-03-25 Johnson & Johnson Consumer Inc Método para la fabricación de un comprimido mediante radiofrecuencia y partículas recubiertas con pérdida
FR3027802B1 (fr) * 2014-10-31 2018-03-02 Ethypharm Granules de principe actif a double masquage de gout, leur procede de preparation et comprimes orodispersibles les contenant
CN104473895A (zh) * 2014-11-20 2015-04-01 美吉斯制药（厦门）有限公司 拉莫三嗪口腔崩解缓释片
CN104645336B (zh) * 2015-01-04 2017-08-29 深圳市药品检验研究院 一种复合辅料及其制备方法和用途
CN104622825A (zh) * 2015-02-09 2015-05-20 鲁南贝特制药有限公司 一种阿奇霉素分散片
CN104940128A (zh) * 2015-05-31 2015-09-30 黑龙江佰彤儿童药物研究有限公司 一种拉莫三嗪口服液体制剂及其制备方法
WO2017017679A1 (en) * 2015-07-29 2017-02-02 Dexcel Pharma Technologies Ltd. Compositions comprising atorvastatin or a pharmaceutically acceptable salt thereof
CA3036085A1 (en) 2015-09-11 2017-03-16 Andrew Guise An oral particulate composition
MX2019000219A (es) * 2016-07-05 2019-09-04 Glaxosmithkline Consumer Healthcare Holdings Us Llc Forma de dosificación oral que contiene un revestimiento exterior de liberación rápida.
CN107625786A (zh) * 2016-07-18 2018-01-26 北京科信必成医药科技发展有限公司 一种碳酸钙维生素d3组合物及其无水吞服颗粒
CN107625734B (zh) * 2016-07-19 2022-02-18 北京科信必成医药科技发展有限公司 一种无水吞服掩味制剂及其制备方法
JP6606287B2 (ja) 2016-07-27 2019-11-13 沢井製薬株式会社 口腔内崩壊錠添加用組成物
WO2018047789A1 (ja) * 2016-09-06 2018-03-15 沢井製薬株式会社 口腔内崩壊錠添加用組成物
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US20200214985A1 (en) * 2017-08-21 2020-07-09 Nipro Corporation Pharmaceutical composition particles, orally disintegrating preparation containing same, and method for producing pharmaceutical composition particles
WO2021222739A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
WO2022008966A1 (en) * 2020-07-06 2022-01-13 Reema Sinha N - [4 - (trifluoromethoxy) benzylidene) nicotinohydrazide composition for oral administration
CN113456603A (zh) * 2021-07-02 2021-10-01 安徽省先锋制药有限公司 一种拉莫三嗪分散片的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282071B6 (sk) * 1991-01-30 2001-10-08 The Wellcome Foundation Limited Tableta dispergovateľná vo vode a spôsob jej prípravy
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
EP1007012A4 (en) 1996-10-01 2006-01-18 Cima Labs Inc TASTE-MASKED MICRO-CAPSULE COMPOSITION AND MANUFACTURING PROCESS
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004103340A1 (en) 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
CA2562213A1 (en) * 2004-04-06 2005-11-24 Rpg Life Sciences Limited Mouth dissolvable and meltable, and water dispersable delivery formulation
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
NZ589750A (en) * 2004-10-21 2012-07-27 Aptalis Pharmatech Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
IS7724A (is) * 2005-03-02 2006-09-03 Actavis Group Samsetning á töflum með hraða sundrun sem innihalda þungt magnesíum karbónat
CA2631492A1 (en) 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7919155B2 (en) * 2007-03-07 2011-04-05 Xerox Corporation Document and method of making document including invisible information for security applications
TWI547282B (zh) 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物

Also Published As

Publication number Publication date
US20160256464A1 (en) 2016-09-08
TW200911267A (en) 2009-03-16
US9339504B2 (en) 2016-05-17
SA08290401B1 (ar) 2013-12-10
CN101801192A (zh) 2010-08-11
US20090092672A1 (en) 2009-04-09
HK1147026A1 (en) 2011-07-22
CL2008001966A1 (es) 2009-03-20
US20100303905A1 (en) 2010-12-02
EP2173172A4 (en) 2012-11-07
US20130108703A1 (en) 2013-05-02
TWI547282B (zh) 2016-09-01
AU2008272871B2 (en) 2014-08-07
AU2008272871A1 (en) 2009-01-08
EP2173172A1 (en) 2010-04-14
US8647656B2 (en) 2014-02-11
CN104161733A (zh) 2014-11-26
WO2009006516A1 (en) 2009-01-08
BRPI0814408A2 (pt) 2017-05-09
US20140220144A1 (en) 2014-08-07
CN101801192B (zh) 2014-07-02
NZ582458A (en) 2012-09-28
AR068185A1 (es) 2009-11-11
UY31205A1 (es) 2008-11-28
JP2010532384A (ja) 2010-10-07
CA2693072A1 (en) 2009-01-08
US7919115B2 (en) 2011-04-05
US8840925B2 (en) 2014-09-23
JP5346021B2 (ja) 2013-11-20
JP2013241462A (ja) 2013-12-05
CA2693072C (en) 2016-09-06

Similar Documents

Publication Publication Date Title
HK1201745A1 (en) Orally disintegrating tablet compositions of lamotrigine
EP2218443A4 (en) COMPRESSED ORALLY DISINTEGRATING
IL194355A0 (en) Orally disintegrating tablets
HK1155978A1 (en) Orally disintegrating tablets
EP2098250A4 (en) ORAL CRACKING SOLID PREPARATION
IL207989A0 (en) Orally disintegrating solid preparation
EP2034953A4 (en) ORAL DISINTEGRATING LAYER COMPOSITIONS
EP2465539A4 (en) DISINTEGRATING PARTICLE COMPOSITION AND COMPRESSED RAPIDLY DISINTEGRATING IN THE ORAL CAVITY
EP2429586A4 (en) MELTING AUXILIARY SUBSTANCE
EP2133096A4 (en) IN THE MOUTHING TABLET
HK1169811A1 (en) The orally rapidly disintegrating tablet that contains two or more types of particles
BRPI0821761A2 (pt) Composições de comprimidos de desintegração oral de temazepam
PT2415466T (pt) Comprimido revestido que se desintegra oralmente
EP2196221A4 (en) SOLID PREPARATION WITH QUICK DISINTEGRATION
ZA201304617B (en) Orally disintegrating tablet
HK1171955A1 (zh) 可口腔轉化的片劑
PT2395834T (pt) Composições farmacêuticas contendo nitrito de sódio
EP2510950A4 (en) DRY-COATED MOUTH-CATCHING TABLET
EP2465540A4 (en) DISINTEGRATING PARTICLE COMPOSITION AND COMPRESSED RAPIDLY DISINTEGRATING IN THE ORAL CAVITY
EP2246052A4 (en) RAPID DISINTEGRATION ORAL ADMINISTRATION TABLET CONTAINING IMIDAFENACIN
ZA201304366B (en) Orally disintegrating tablet
ZA201002897B (en) Prevention of allergy at weaning
IL212735A0 (en) Capecitabine rapidly disintegrating tablets
EP2382971A4 (en) ORAL DISINTEGRATING TABLE COMPRISING AN INDOOR CORE
EP2409688A4 (en) COMPRESSED ORAL DISCLAIMER